天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Aladdin Scientific

Firmenname:Aladdin Scientific
Telefon:552-7181
E-Mail:sales@aladdinsci.com
Nationalit?t:United States
URL: www.aladdinsci.com/
Produkte insgesamt:57505
484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576

Produktkatalog

Pascolizumab (anti-IL-4)331243-22-2
Lemzoparlimab (anti-CD47)2377483-71-9
Otilimab (anti-GM-CSF)1638332-55-4
Gantenerumab (anti-Amyloid Beta)1043556-46-2
Rilotumumab (anti-HGF)872514-65-3
Gevokizumab (anti-IL-1b)1129435-60-4
Carotuximab (anti-CD105)1268714-50-6
Inebilizumab (anti-CD19)1299440-37-1
Zansecimab (anti-ANGPT2)2415205-37-5
Imaprelimab (anti-CD146)2014343-04-3
Eculizumab (anti-Complement C5)219685-50-4
Ontamalimab (anti-MADCAM1)2098790-40-8
Tarextumab (anti-NOTCH3)1359940-55-8
Bermekimab (anti-IL-1a)1401965-15-8
Cusatuzumab (anti-CD70)1864871-20-4
Denintuzumab (anti-CD19)1630074-14-4
Gemtuzumab (anti-CD33)220578-59-6
Enfortumab (anti-NECTIN4)1448664-46-7
Teprotumumab (anti-IGF1R)1036734-93-6
Sirukumab (anti-IL-6)1194585-53-9
Teplizumab (anti-CD3e)876387-05-2
Tinurilimab (anti-CEACAM6)2226224-30-0
Eldelumab (anti-CXCL10)946414-98-8
Emibetuzumab (anti-MET)1365287-97-3
Vantictumab (anti-FZD)1345009-45-1
Indusatumab (anti-GUCY2C)1497400-26-6
Labetuzumab govitecan (anti-CEACAM5)1469876-18-3
Prezalumab (anti-B7-H2)1523164-68-2
Mezagitamab (anti-CD38)2227490-52-8
Depatuxizumab mafodotin (anti-EGFR)1585973-65-4
Avdoralimab (anti-C5AR1)2226393-85-5
Polatuzumab (anti-CD79b)2279068-37-8
Daclizumab (anti-IL2RA)152923-56-3
Seribantumab (anti-ERBB3)1334296-12-6
Abelacimab(anti-Factor XI)2098724-83-3
Enoblituzumab (anti-CD276)1353485-38-7
Dinutuximab (anti-GD2)1363687-32-4
Fulranumab (anti-NGF)902141-80-4
Lorvotuzumab (anti-CD56)339306-30-8
Dostarlimab (anti-PD-1)2022215-59-2
Datopotamab (anti-TROP2)2267989-53-5
Enokizumab (anti-IL-9)909875-08-7
Brazikumab (anti-IL-23)1610353-18-8
Belimumab (anti-TNFSF13B)356547-88-1
Ulocuplumab (anti-CXCR4)1375830-34-4
Ponsegromab (anti-GDF15)2368950-15-4
Ocrelizumab (anti-CD20)637334-45-3C19H16N2O5
Girentuximab (anti-CA9)916138-87-9
Efalizumab (anti-ITGAL)214745-43-4
Vunakizumab (anti-IL-17a)1792181-33-9
Envafolimab (anti-PD-L1)2102192-68-5
Talquetamab (anti-GPRC5D)2226212-40-2
Figitumumab (anti-IGF1R)943453-46-1
Panitumumab (anti-EGFR)339177-26-3
Farletuzumab (anti-FOLR1)896723-44-7
Muromonab (anti-CD3)140608-64-6
Sotigalimab (anti-CD40)2305607-45-6
Anifrolumab (anti-IFNAR1)1326232-46-5
Brentuximab (anti-TNFRSF8)2088770-90-3
Onvatilimab (anti-VISTA)1969313-51-6
Patritumab (anti-ERBB3)1262787-83-6
Fletikumab (anti-IL-20)1357158-22-5
Abituzumab (anti-ITGAV)1105038-73-0
Mirvetuximab (anti-FOLR1)1453084-36-0
Sofituzumab (anti-MUC16)1615692-28-8
Margetuximab (anti-HER2)1350624-75-7
Emicizumab (anti-Factor IX)1610943-06-0
Onartuzumab (anti-MET)1133766-06-9
Ficlatuzumab (anti-HGF)1174900-84-5
Zilovertamab (anti-ROR1)2485779-13-1
Simtuzumab (anti-LOXL2)1318075-13-6
Mavrilimumab (anti-CD116)1085337-57-0
Relatlimab (anti-LAG-3/CD223)1673516-98-7
Belantamab (anti-TNFRSF17)2061894-48-0
Motavizumab (anti-RSV-F)677010-34-3
Varlilumab (anti-TNFRSF7)1393344-72-3
Mepolizumab (anti-IL-5)196078-29-2
Eptinezumab (anti-CGRP)1644539-04-7
Ofatumumab (anti-CD20)679818-59-8
Ibalizumab (anti-CD4)680188-33-4
Omburtamab (anti-CD276)1895083-75-6
Penpulimab (anti-PDCD1)2350298-92-7
Erenumab (anti-CALCRL)1582205-90-0
Selicrelumab (anti-CD40)1622140-49-1
Sifalimumab (anti-IFNa1)1006877-41-3
Nadunolimab (anti-IL-1 RAcP)2171061-85-9
Canakinumab (Anti-IL-1b)914613-48-2
Oleclumab (anti-CD73)1803176-05-7
Olokizumab (anti-IL-6)1007223-17-7
Fezakinumab (anti-IL-22)1007106-86-6
Mupadolimab (anti-CD73)2451856-97-4
Bemarituzumab (anti-FGFR2)1952272-74-0
Aducanumab (anti-APP)1384260-65-4
Etokimab (anti-IL-33)2022981-44-6
Rovalpituzumab (anti-DLL3)1613313-01-1
Otelixizumab (anti-CD3)881191-44-2
Aprutumab (anti-FGFR2)1634620-63-5
Etrolizumab (anti-α4β7)1044758-60-2
Amatuximab (anti-MSLN)931402-35-6
Naxitamab (anti-GD2)1879925-92-4
484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576
Copyright 2019 ? ChemicalBook. All rights reserved